Search

Your search keyword '"Shepherd, F.A."' showing total 6 results
Start Over Author "Shepherd, F.A." Publisher mdpi ag
6 results on '"Shepherd, F.A."'

1. Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment

Author

Tse, B.C., primary, Said, B.I., additional, Fan, Z.J., additional, Hueniken, K., additional, Patel, D., additional, Gill, G., additional, Liang, M., additional, Razooqi, M., additional, Brown, M.C., additional, Sacher, A.G., additional, Bradbury, P.A., additional, Shepherd, F.A., additional, Leighl, N.B., additional, Xu, W., additional, Howell, D., additional, Liu, G., additional, and O’Kane, G., additional

Published
2020
Full Text
View/download PDF

3. Somatic alteration burden involving non-cancer genes predicts prognosis in early-stage non-small cell lung cancer

Author

Wang, D., Pham, N.-A., Freeman, T.M., Raghavan, V., Navab, R., Chang, J., Zhu, C.-Q., Ly, D., Tong, J., Wouters, B.G., Pintilie, M., Moran, M.F., Liu, G., Shepherd, F.A., and Tsao, M.-S.

Abstract

The burden of somatic mutations and neoantigens has been associated with improved survival in cancer treated with immunotherapies, especially non-small cell lung cancer (NSCLC). However, there is uncertainty about their effect on outcome in early-stage untreated cases. We posited that the burden of mutations in a specific set of genes may also contribute to the prognosis of early NSCLC patients. From a small cohort of 36 NSCLC cases, we were able to identify somatic mutations and copy number alterations in 865 genes that contributed to patient overall survival. Simply, the number of altered genes (NAG) among these 865 genes was associated with longer disease-free survival (hazard ratio (HR) = 0.153, p = 1.48 × 10−4). The gene expression signature distinguishing patients with high/low NAG was also prognostic in three independent datasets. Patients with a high NAG could be further stratified based on the presence of immunogenic mutations, revealing a further subgroup of stage I NSCLC with even better prognosis (85% with >5 years survival), and associated with cytotoxic T-cell expression. Importantly, 95% of the highly-altered genes lacked direct relation to cancer, but were implicated in pathways regulating cell proliferation, motility and immune response.

Published
2019

4. Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort

Author

Juergens, R.A., primary, Mariano, C., additional, Jolivet, J., additional, Finn, N., additional, Rothenstein, J., additional, Reaume, M.N., additional, Faghih, A., additional, Labbé, C., additional, Owen, S., additional, Shepherd, F.A., additional, Villeneuve, J., additional, Romeyer, F., additional, Pettersson, F., additional, and Butts, C., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results